Human Recombinant LOXL4 protein, GST Tag (V2LY-0526-LY5338)

Ma, H. Y., Li, Q., Wong, W. R., N’Diaye, E. N., Caplazi, P., Bender, H., ... & Ding, N. (2023). LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung. Science Advances, 9(21), eadf0133.

Wang, J., Chen, C., Huang, J., Xie, Z., Chen, X., Zheng, Z., ... & Zou, H. (2023). The possibilities of LOXL4 as a prognostic marker for carcinomas. Amino Acids, 1-11.

Altuntaş, O. M., Süslü, N., Tezel, Y. G. G., Dogan, H. T., & Yılmaz, T. (2022). Lysyl Oxidase Like-4 (LOXL4) as a tumor marker and prognosticator in advanced stage laryngeal cancer. Brazilian Journal of Otorhinolaryngology, 88, 968-974.

Ji, Y., You, Y., Wu, Y., Wang, M., He, Q., Zhou, X., ... & Zhao, X. (2022). Overexpression of miR-328-5p influences cell growth and migration to promote NSCLC progression by targeting LOXL4. Annals of Translational Medicine, 10(6).

Yin, H., Wang, Y., Wu, Y., Zhang, X., Zhang, X., Liu, J., ... & Zhang, R. (2020). EZH2-mediated epigenetic silencing of miR-29/miR-30 targets LOXL4 and contributes to tumorigenesis, metastasis, and immune microenvironment remodeling in breast cancer. Theranostics, 10(19), 8494.

Li, R., Wang, Y., Zhang, X., Feng, M., Ma, J., Li, J., ... & Jiang, S. (2019). Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Molecular cancer, 18(1), 1-19.

Shao, J., Lu, J., Zhu, W., Yu, H., Jing, X., Wang, Y. L., ... & Wang, X. J. (2019). Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53. Cell Death & Differentiation, 26(11), 2237-2252.

Xie, W., Huang, P., Wu, B., Chen, S., Huang, Z., Wang, J., ... & Zou, H. (2019). Clinical significance of LOXL4 expression and features of LOXL4-associated protein–protein interaction network in esophageal squamous cell carcinoma. Amino Acids, 51, 813-828.

Zhang, Y., Jiang, W. L., Yang, J. Y., Huang, J., Kang, G., Hu, H. B., & Xie, S. (2019). Downregulation of lysyl oxidase‐like 4 LOXL4 by miR‐135a‐5p promotes lung cancer progression in vitro and in vivo. Journal of Cellular Physiology, 234(10), 18679-18687.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols